Avalere
CMS's 340B Payment Proposal Could Squeeze Hospitals on High-Cost Drugs, With Medicaid Rebate Ties
The analysis examines CMS's proposed CY2027 OPPS rule to reimburse 340B drugs at ASP minus 33.4%, showing that this flat benchmark may not match actual acquisition costs across therapeutic classes, with some drug categories facing underpayment relative to real costs. It notes how 340B ceiling prices are calculated using Medicaid Average Manufacturer Price and rebate amounts, meaning deeper Medicaid rebates can push 340B prices even lower, creating ripple effects relevant to drug pricing and rebate policy that touch Medicaid programs indirectly.
This is outside commentary from Avalere, not part of Medicaid Monitor's independently scored news coverage.